Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ: CLDX )

20.57 +0.26 (+1.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,329,020
Open 19.90
Bid (Size) 19.22 (1)
Ask (Size) 20.92 (2)
Prev. Close 20.31
Today's Range 19.82 - 20.59
52wk Range 19.82 - 53.18
Shares Outstanding 66,344,236
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics
Via Benzinga

Performance

YTD
-20.24%
-20.24%
1 Month
-18.57%
-18.57%
3 Month
-24.46%
-24.46%
6 Month
-50.43%
-50.43%
1 Year
-60.35%
-60.35%

More News

Read More
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews
Via Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
Via Benzinga
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
Via Benzinga
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Via Benzinga
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations For Celldex Therapeutics's Future
Via Benzinga
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
Via Benzinga
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts
Via Benzinga
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
7 Analysts Have This To Say About Celldex Therapeutics
Via Benzinga
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.